Stock ARVN ARVINAS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Arvinas, Inc.

Equities

ARVN

US04335A1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
32.54 USD -4.15% Intraday chart for Arvinas, Inc. -2.72% -20.94%
Apr. 15 H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating MT
Apr. 12 HC Wainwright Adjusts Arvinas' Price Target to $87 From $90, Keeps Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
GL
Arvinas : 2024 Proxy Statement
PU
H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating
MT
HC Wainwright Adjusts Arvinas' Price Target to $87 From $90, Keeps Buy Rating
MT
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer
AQ
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug
MT
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
AQ
Wedbush Adjusts Arvinas' Price Target to $57 From $59, Keeps Outperform Rating
MT
Novartis: licensing agreement in prostate cancer
CF
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis
MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion
RE
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
GL
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer
CI
Arvinas Appoints Noah Berkowitz as Chief Medical Officer
MT
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
GL
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee
CI
Transcript : Arvinas, Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 09:00 AM
Arvinas to Participate in Upcoming Investor Conferences
GL
Barclays Adjusts Arvinas' Price Target to $60 From $26, Maintains Overweight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARVN Stock
  4. News Arvinas, Inc.